Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes will present two oral presentations and six posters on alixorexton and LUMRYZ at the ESRS Sleep Europe 2026 congress (Oct. 20-23, Maastricht). The orals cover Vibrance-1 Phase 2 data on alixorexton in narcolepsy type 1, nine-month long-term extension results, and detailed Phase 3 REVITALYZ results of LUMRYZ in idiopathic hypersomnia, whose positive topline was previously announced. Alixorexton holds FDA Breakthrough Therapy designation for NT1 and Orphan Drug status, and is in Phase 3 Brilliance trials plus Phase 2 Vibrance-3 in IH.
Key figures
- Drug Name
- Alixorexton (ALKS 2680); LUMRYZ (sodium oxybate)
- Phase Of Trial
- Phase 2 (Vibrance-1/Vibrance-2), Phase 3 (REVITALYZ, Brilliance)
- Presentations
- 2 oral presentations and 6 posters
- Lte duration months
- 9
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.